Drugs / Reference Euthyrox®
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05174000 | Jan → Oct 2022 | — | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Reference Euthyrox | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05174000 ↗ |
| Route | Oral | “Administered Orally as 12 Tablets of 50 μg” NCT05174000 ↗ |